ClinicalTrials.gg
CompletedNCT03855137Updated Feb 14, 2023Results posted

Efficacy, Safety, and Tolerability of Atogepant for the Prevention of Chronic Migraine

A Phase 3 interventional study of Atogepant 30 mg and Atogepant 60 mg in Chronic Migraine, sponsored by Allergan. Completed at 150 sites in 17 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2023-02-14.

Sponsored by Allergan (part of AbbVie) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
778
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies testing atogepant in Migraine Disorders — 6 open to participants now, 7 under way, 4 of them phase 3. atogepant · Migraine Disorders.

Enrollment
5th of 21
778 · median 468
Started
2019
with 1 other
Phase 3
15 of 21
3 open now
Registered
4th of 21
by date
Lead sponsor
7 of 21
Allergan

Among the 21 studies testing atogepant in Migraine Disorders, this one is the 5th largest by enrollment, is one of 2 that started in 2019, is one of 15 in phase 3, and was the 4th registered.

Migraine Disorders

1,658 studies on the registry are indexed under Migraine Disorders; 340 are open to participants now.

Browse Migraine Disorders studies →

Open to participants now

6 of the 21 studies testing atogepant in Migraine Disorders are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About atogepant

atogepant: first FDA approval 2021 (QULIPTA), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing atogepant in Migraine Disorders, or all of them as a file.
02

Study summary

This study evaluated the efficacy, safety and tolerability of atogepant in participants with chronic migraine. This study included a 12-week treatment period.

03

Conditions studied

  • Chronic Migraine

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • At least a 1-year history of chronic migraine (CM) consistent with a diagnosis according to the International Classification of Headache Disorders, 3rd Edition (ICHD-3), 2018
  • Age of the participant at the time of migraine onset \< 50 years
  • Confirmation of headache/migraine headache day frequency as follows:

    • History of, on average, ≥ 15 headache days per month in the 3 months prior to Visit 1 in the opinion of the investigator AND
    • >=15 headache days during the 4-week screening/baseline period per the electronic diary (eDiary) AND
    • >=8 days during the 4-week screening/baseline period that qualify as being a migraine day per the eDiary
  • Participants must be using a medically acceptable and effective method of during the course of the entire study

Exclusion criteria

Exclusion Criteria:

  • Has a history of migraine, accompanied by diplopia or decreased level of consciousness, or retinal migraine
  • Has a current diagnosis of new persistent daily headache, trigeminal autonomic cephalgia (eg, cluster headache), or painful cranial neuropathy
  • History of an inadequate response to > 4 medications (2 of which have different mechanisms of action) prescribed for the prevention of migraine
  • Woman is pregnant, planning to become pregnant during the course of the study, or currently lactating. Women of must have a negative urine pregnancy test at Visit 1 and Visit 2.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
778 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Participants received atogepant-matching placebo tablets, orally, twice daily (BID) for 12 weeks in a double-blind (DB) treatment period.

    Drug: Placebo

  • Active comparator
    Atogepant 30 mg BID

    Participants received atogepant 30 mg tablet, orally, BID and atogepant-matching placebo tablets orally, BID for up to 12 weeks in a DB treatment period.

    Drug: Atogepant 30 mg · Drug: Placebo

  • Active comparator
    Atogepant 60 mg QD

    Participants received atogepant 60 mg, orally, once daily (QD) along with atogepant-matching placebo 30 mg as morning dose followed by atogepant-matching placebo 30 mg and 60 mg as evening doses for up to 12 weeks in a DB treatment period.

    Drug: Atogepant 60 mg · Drug: Placebo

Interventions

  • Tablets containing 30 mg atogepant

  • Tablets containing 60 mg atogepant

  • DrugPlacebo

    30 mg/60 mg tablets containing atogepant-matching placebo

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Mean Monthly Migraine Days Across 12-Week Treatment Period in mITT Population

    Participants recorded daily duration of migraine in a diary. A migraine day was any calendar day on which the participant experienced a migraine headache. The monthly (4-week) migraine days were defined as the total number of reported migraine days in diary divided by total number of days with diary records during each 4-week period and multiplied by 28. Each 4-week period was averaged. Baseline is defined as the number of migraine days during the last 28 days prior to the randomization date. Negative change from Baseline indicates improvement. A contrast from Mixed-effects model for repeated measures (MMRM) was used to obtain the average treatment effects across the 12-week treatment period.

    Time frame: Baseline to Week 12

  2. Change From Baseline in Mean Monthly Migraine Days Across 12-Week Treatment Period in Off-Treatment Hypothetical Estimand Population

    Participants recorded daily duration of migraine in a diary. A migraine day was any calendar day on which the participant experienced a migraine headache. The monthly (4-week) migraine days were defined as the total number of reported migraine days in diary divided by total number of days with diary records during each 4-week period and multiplied by 28. Each 4-week period was averaged. Baseline is defined as the number of migraine days during the last 28 days prior to the randomization date. Negative change from Baseline indicates improvement. A contrast from Mixed-effects model for repeated measures (MMRM) was used to obtain the average treatment effects across the 12-week treatment period.

    Time frame: Baseline to Week 12

Secondary outcomes

  1. Change From Baseline in Mean Monthly Headache Days Across 12-Week Treatment Period in mITT Population

    Participants recorded daily total duration of a headache in a diary. A headache day is any calendar day on which the participant experienced a headache pain lasting 2 hours or longer unless an acute headache medication was used after the start of the headache. The monthly (4-week) headache days were defined as the total number of reported headache days in the diary divided by the total number of days with diary records during each 4-week period and multiplied by 28. Each 4-week period was averaged. Baseline is defined as the number of headache days during the last 28 days prior to the randomization date. Negative change from Baseline indicates improvement. A contrast from MMRM was used to obtain the average treatment effects across the 12-week treatment period.

    Time frame: Baseline to Week 12

  2. Change From Baseline in Mean Monthly Headache Days Across 12-Week Treatment Period in Off-Treatment Hypothetical Estimand Population

    Participants recorded daily total duration of a headache in a diary. A headache day is any calendar day on which the participant experienced a headache pain lasting 2 hours or longer unless an acute headache medication was used after the start of the headache. The monthly (4-week) headache days were defined as the total number of reported headache days in the diary divided by the total number of days with diary records during each 4-week period and multiplied by 28. Each 4-week period was averaged. Baseline is defined as the number of headache days during the last 28 days prior to the randomization date. Negative change from Baseline indicates improvement. A contrast from MMRM was used to obtain the average treatment effects across the 12-week treatment period.

    Time frame: Baseline to Week 12

  3. Change From Baseline in Mean Monthly Acute Medication Use Days Across 12-Week Treatment Period in mITT Population

    An acute medication use day is defined as any day on which a participant reports, per eDiary, the intake of allowed medication(s) to treat an acute migraine. The monthly (4-week) acute medication use days were defined as the total number of reported acute medication use days in the diary divided by the total number of days with diary records during each 4-week period and multiplied by 28. Each 4-week period was averaged. Baseline is defined as the number of migraine days during the last 28 days prior to the randomization date. A negative change from Baseline indicates improvement. A contrast from MMRM was used to obtain the average treatment effects across the 12-week treatment period.

    Time frame: Baseline to Week 12

  4. Change From Baseline in Mean Monthly Acute Medication Use Days Across 12-Week Treatment Period in Off-treatment Hypothetical Estimand Population

    An acute medication use day is defined as any day on which a participant reports, per eDiary, the intake of allowed medication(s) to treat an acute migraine. The monthly (4-week) acute medication use days were defined as the total number of reported acute medication use days in the diary divided by the total number of days with diary records during each 4-week period and multiplied by 28. Each 4-week period was averaged. Baseline is defined as the number of migraine days during the last 28 days prior to the randomization date. A negative change from Baseline indicates improvement. A contrast from MMRM was used to obtain the average treatment effects across the 12-week treatment period.

    Time frame: Baseline to Week 12

  5. Percentage of Participants With at Least a 50% Reduction in 3-Month Average of Monthly Migraine Days in mITT Population

    Data is reported for 50% responders averaged at each 4-week period. 50% responders are participants with at least a 50 percent reduction from baseline in 3-month average of monthly migraine days. Participants recorded daily duration of migraine in a diary. A migraine day was any calendar day on which the participant experienced a migraine headache. The monthly (4-week) migraine days is equal to total number of reported migraine days in diary divided by total number of days with diary records in each 4-week period multiplied by 28. The values are rounded off to the first decimal value.

    Time frame: Baseline to Week 12

  6. Percentage of Participants With at Least a 50% Reduction in 3-Month Average of Monthly Migraine Days in Off-Treatment Hypothetical Estimand Population

    Data is reported for 50% responders averaged at each 4-week period. 50% responders are participants with at least a 50 percent reduction from baseline in 3-month average of monthly migraine days. Participants recorded daily duration of migraine in a diary. A migraine day was any calendar day on which the participant experienced a migraine headache. The monthly (4-week) migraine days is equal to total number of reported migraine days in diary divided by total number of days with diary records in each 4-week period multiplied by 28. The values are rounded off to the first decimal value.

    Time frame: Baseline to Week 12

  7. Change From Baseline in Migraine Specific Quality of Life Questionnaire, Version 2.1 (MSQ v2.1) Role Function-Restrictive Domain Score at Week 12 in Off-Treatment Hypothetical Estimand Population

    The MSQ v2.1 is a 14-item questionnaire designed to measure health-related quality of life impairments attributed to migraine in the past 4 weeks. It is divided into 3 domains: Role Function Restrictive (question numbers 1-7, score ranges 7 to 42) assesses how migraines limit one's daily social and work-related activities; Role Function Preventive (question numbers 8-11, score ranges 4 to 24) assesses how migraines prevent these activities; and the Emotional Function (question numbers 12-14, score ranges 3 to 18) domain assesses the emotions associated with migraines. Participants respond to items using a 6-point scale ranging from none of the time to all of the time. Raw dimension scores are computed as a sum of item responses and rescaled to a 0 to 100 scale, where higher scores indicate better quality of life. A contrast from MMRM was used to obtain the average treatment effects across the 12-week treatment period.

    Time frame: At Week 12

  8. Change From Baseline in Mean Monthly Performance of Daily Activities Domain Score of the AIM-D Across 12-Week Treatment Period in mITT Population

    The AIM-D is a 11-item patient-reported outcome (PRO) measure that assesses the impact of migraine on the performance of daily activities which include, 7 items: difficulty with household chores, errands, leisure activities at home, leisure or social activities outside the home, strenuous physical activities, concentrating, and thinking clearly and physical impairment; 4 items: difficulty walking, moving body, bending forward, moving head using a 6-point rating scale where 0=not difficult at all, 1=a little difficult, 2=somewhat difficult, 3=very difficult, 4=extremely difficult, and 5=I could not do it at all. The raw performance of daily activities domain scores were transformed to 0-100 scale, with higher scores indicating greater impact of migraine (higher disease burden). A contrast from MMRM was used to obtain the average treatment effects across the 12-week treatment period.

    Time frame: Baseline to Week 12

  9. Change From Baseline in Mean Monthly Physical Impairment Domain Score of the AIM-D Across 12-Week Treatment Period in mITT Population

    The AIM-D is a 11-item PRO measure that assesses the impact of migraine on the performance of daily activities which includes 7 items: difficulty with household chores, errands, leisure activities at home, leisure or social activities outside the home, strenuous physical activities, concentrating, and thinking clearly and physical impairment; 4 items: difficulty walking, moving body, bending forward, moving head using a 6-point rating scale where 0=not difficult at all, 1=a little difficult, 2=somewhat difficult, 3=very difficult, 4=extremely difficult, and 5=I could not do it at all. The raw physical impairment domain scores were transformed to 0-100 scale, with higher scores indicating greater impact of migraine (higher disease burden). A contrast from MMRM was used to obtain the average treatment effects across the 12-week treatment period.

    Time frame: Baseline to Week 12

  10. Change From Baseline in the Headache Impact Test (HIT-6) Total Score at Week 12 in Off-Treatment Hypothetical Estimand Population

    HIT-6 is a 6-question assessment used to measure the impact headaches have on a participant's ability to function on the job, at school, at home, and in social situations. It assesses the effect that headaches have on normal daily life and the participant's ability to function. Responses are based on frequency using a 5-point scale ranging from "never" to "always." The HIT-6 total score, which ranges from 36 to 78, is the sum of the responses - each of which is assigned a score ranging from 6 points (never) to 13 points (always). MMRM was used for the analyses.

    Time frame: At Week 12

07

Results

Posted Feb 14, 2023

Participant flow

DB Treatment Period (Day 1 to Week 12)
Participant flow — DB Treatment Period (Day 1 to Week 12)
MilestonePlaceboAtogepant 30 mg BIDAtogepant 60 mg QD
Started259257262
Safety population255257261
Modified intent-to-treat (mitt) population246253256
Off-treatment hypothetical estimand population249254257
Completed230231233
Not completed292629
Withdrew: Adverse event10139
Withdrew: Lack of efficacy521
Withdrew: Withdrawal by subject8714
Withdrew: Lost to follow-up013
Withdrew: Protocol deviation532
Withdrew: Non-compliance with study drug100
FU Period (Week 12 to Week 16)
Participant flow — FU Period (Week 12 to Week 16)
MilestonePlaceboAtogepant 30 mg BIDAtogepant 60 mg QD
Started169179169
Completed161170165
Not completed894
Withdrew: Withdrawal by subject563
Withdrew: Lost to follow-up031
Withdrew: Protocol deviation200
Withdrew: Reason not specified100

Outcome measures

PrimaryChange From Baseline in Mean Monthly Migraine Days Across 12-Week Treatment Period in mITT Population

Participants recorded daily duration of migraine in a diary. A migraine day was any calendar day on which the participant experienced a migraine headache. The monthly (4-week) migraine days were defined as the total number of reported migraine days in diary divided by total number of days with diary records during each 4-week period and multiplied by 28. Each 4-week period was averaged. Baseline is defined as the number of migraine days during the last 28 days prior to the randomization date. Negative change from Baseline indicates improvement. A contrast from Mixed-effects model for repeated measures (MMRM) was used to obtain the average treatment effects across the 12-week treatment period.

Time frame:
Baseline to Week 12
Reported as:
Median · migraine days per month
Change From Baseline in Mean Monthly Migraine Days Across 12-Week Treatment Period in mITT Population
migraine days per monthPlaceboAtogepant 30 mg BIDAtogepant 60 mg QD
Change From Baseline in Mean Monthly Migraine Days Across 12-Week Treatment Period in mITT Population-4.63 (-21.9 to 9.7)-7.13 (-27.0 to 7.7)-7.27 (-22.3 to 12.9)
Statistical analysis
  • Placebo vs Atogepant 30 mg BID · Mixed Model Repeated Measures (MMRM) · p = 0.0001 (Adjusted p-value using graphical approach to control the overall type 1 error rate for multiple comparisons.) · Least squares mean difference: -2.41 · 95% CI -3.48 to -1.33MMRM model=treatment group,visit,stratification by acute medication overuse,migraine prevention medication use and number of failures,region,and treatment group-by-visit as fixed factors and baseline and baseline-by-visit interaction as covariates.
  • Placebo vs Atogepant 60 mg QD · MMRM · p = 0.0009 (Adjusted p-value using graphical approach to control the overall type 1 error rate for multiple comparisons.) · Least squares mean difference: -1.82 · 95% CI -2.89 to -0.75MMRM model=treatment group,visit,stratification by acute medication overuse,migraine prevention medication use and number of failures,region,and treatment group-by-visit as fixed factors and baseline and baseline-by-visit interaction as covariates.
PrimaryChange From Baseline in Mean Monthly Migraine Days Across 12-Week Treatment Period in Off-Treatment Hypothetical Estimand Population

Participants recorded daily duration of migraine in a diary. A migraine day was any calendar day on which the participant experienced a migraine headache. The monthly (4-week) migraine days were defined as the total number of reported migraine days in diary divided by total number of days with diary records during each 4-week period and multiplied by 28. Each 4-week period was averaged. Baseline is defined as the number of migraine days during the last 28 days prior to the randomization date. Negative change from Baseline indicates improvement. A contrast from Mixed-effects model for repeated measures (MMRM) was used to obtain the average treatment effects across the 12-week treatment period.

Time frame:
Baseline to Week 12
Reported as:
Median · migraine days per month
Change From Baseline in Mean Monthly Migraine Days Across 12-Week Treatment Period in Off-Treatment Hypothetical Estimand Population
migraine days per monthPlaceboAtogepant 30 mg BIDAtogepant 60 mg QD
Change From Baseline in Mean Monthly Migraine Days Across 12-Week Treatment Period in Off-Treatment Hypothetical Estimand Population-4.65 (-21.9 to 9.7)-7.00 (-27.0 to 7.7)-7.19 (-22.3 to 12.9)
Statistical analysis
  • Placebo vs Atogepant 30 mg BID · MMRM · p = 0.0001 (Adjusted p-value using graphical approach to control the overall type 1 error rate for multiple comparisons.) · Least squares mean difference: -2.24 · 95% CI -3.31 to -1.16MMRM model=treatment group,visit,stratification by acute medication overuse,migraine prevention medication use and number of failures,region,and treatment group-by-visit as fixed factors and baseline and baseline-by-visit interaction as covariates.
  • Placebo vs Atogepant 60 mg QD · MMRM · p = 0.0024 · Least squares mean difference: -1.66 · 95% CI -2.72 to -0.59MMRM model=treatment group,visit,stratification by acute medication overuse,migraine prevention medication use and number of failures,region,and treatment group-by-visit as fixed factors and baseline and baseline-by-visit interaction as covariates.
SecondaryChange From Baseline in Mean Monthly Headache Days Across 12-Week Treatment Period in mITT Population

Participants recorded daily total duration of a headache in a diary. A headache day is any calendar day on which the participant experienced a headache pain lasting 2 hours or longer unless an acute headache medication was used after the start of the headache. The monthly (4-week) headache days were defined as the total number of reported headache days in the diary divided by the total number of days with diary records during each 4-week period and multiplied by 28. Each 4-week period was averaged. Baseline is defined as the number of headache days during the last 28 days prior to the randomization date. Negative change from Baseline indicates improvement. A contrast from MMRM was used to obtain the average treatment effects across the 12-week treatment period.

Time frame:
Baseline to Week 12
Reported as:
Median · headache days per month
Change From Baseline in Mean Monthly Headache Days Across 12-Week Treatment Period in mITT Population
headache days per monthPlaceboAtogepant 30 mg BIDAtogepant 60 mg QD
Change From Baseline in Mean Monthly Headache Days Across 12-Week Treatment Period in mITT Population-4.26 (-23.7 to 6.7)-7.16 (-26.3 to 9.0)-6.71 (-22.3 to 9.0)
Statistical analysis
  • Placebo vs Atogepant 30 mg BID · MMRM · p = 0.0001 (Adjusted p-value using graphical approach to control the overall type 1 error rate for multiple comparisons.) · Least squares mean difference: -2.32 · 95% CI -3.38 to -1.26MMRM model=treatment group,visit,stratification by acute medication overuse,migraine prevention medication use and number of failures,region,and treatment group-by-visit as fixed factors and baseline and baseline-by-visit interaction as covariates.
  • Placebo vs Atogepant 60 mg QD · MMRM · p = 0.0009 (Adjusted p-value using graphical approach to control the overall type 1 error rate for multiple comparisons.) · Least squares mean difference: -1.87 · 95% CI -2.93 to -0.81MMRM model=treatment group,visit,stratification by acute medication overuse,migraine prevention medication use and number of failures,region,and treatment group-by-visit as fixed factors and baseline and baseline-by-visit interaction as covariates.
SecondaryChange From Baseline in Mean Monthly Headache Days Across 12-Week Treatment Period in Off-Treatment Hypothetical Estimand Population

Participants recorded daily total duration of a headache in a diary. A headache day is any calendar day on which the participant experienced a headache pain lasting 2 hours or longer unless an acute headache medication was used after the start of the headache. The monthly (4-week) headache days were defined as the total number of reported headache days in the diary divided by the total number of days with diary records during each 4-week period and multiplied by 28. Each 4-week period was averaged. Baseline is defined as the number of headache days during the last 28 days prior to the randomization date. Negative change from Baseline indicates improvement. A contrast from MMRM was used to obtain the average treatment effects across the 12-week treatment period.

Time frame:
Baseline to Week 12
Reported as:
Median · headache days per month
Change From Baseline in Mean Monthly Headache Days Across 12-Week Treatment Period in Off-Treatment Hypothetical Estimand Population
headache days per monthPlaceboAtogepant 30 mg BIDAtogepant 60 mg QD
Change From Baseline in Mean Monthly Headache Days Across 12-Week Treatment Period in Off-Treatment Hypothetical Estimand Population-4.33 (-23.7 to 6.7)-7.04 (-26.3 to 9.0)-6.59 (-22.3 to 9.0)
Statistical analysis
  • Placebo vs Atogepant 30 mg BID · MMRM · p = 0.0002 (Adjusted p-value using graphical approach to control the overall type 1 error rate for multiple comparisons.) · Least squares mean difference: -2.14 · 95% CI -3.20 to -1.09MMRM model=treatment group,visit,stratification by acute medication overuse,migraine prevention medication use and number of failures,region,and treatment group-by-visit as fixed factors and baseline and baseline-by-visit interaction as covariates.
  • Placebo vs Atogepant 60 mg QD · MMRM · p = 0.0024 (Adjusted p-value using graphical approach to control the overall type 1 error rate for multiple comparisons.) · Least squares mean difference: -1.72 · 95% CI -2.78 to -0.67MMRM model=treatment group,visit,stratification by acute medication overuse,migraine prevention medication use and number of failures,region,and treatment group-by-visit as fixed factors and baseline and baseline-by-visit interaction as covariates.
SecondaryChange From Baseline in Mean Monthly Acute Medication Use Days Across 12-Week Treatment Period in mITT Population

An acute medication use day is defined as any day on which a participant reports, per eDiary, the intake of allowed medication(s) to treat an acute migraine. The monthly (4-week) acute medication use days were defined as the total number of reported acute medication use days in the diary divided by the total number of days with diary records during each 4-week period and multiplied by 28. Each 4-week period was averaged. Baseline is defined as the number of migraine days during the last 28 days prior to the randomization date. A negative change from Baseline indicates improvement. A contrast from MMRM was used to obtain the average treatment effects across the 12-week treatment period.

Time frame:
Baseline to Week 12
Reported as:
Median · acute medication use days per month
Change From Baseline in Mean Monthly Acute Medication Use Days Across 12-Week Treatment Period in mITT Population
acute medication use days per monthPlaceboAtogepant 30 mg BIDAtogepant 60 mg QD
Change From Baseline in Mean Monthly Acute Medication Use Days Across 12-Week Treatment Period in mITT Population-3.57 (-23.7 to 20.7)-6.23 (-26.1 to 7.4)-6.33 (-26.0 to 14.2)
Statistical analysis
  • Placebo vs Atogepant 30 mg BID · MMRM · p = 0.0001 (Adjusted p-value using graphical approach to control the overall type 1 error rate for multiple comparisons.) · Least squares mean difference: -2.63 · 95% CI -3.63 to -1.63MMRM model=treatment group,visit,stratification by acute medication overuse,migraine prevention medication use and number of failures,region,and treatment group-by-visit as fixed factors and baseline and baseline-by-visit interaction as covariates.
  • Placebo vs Atogepant 60 mg QD · MMRM · p = 0.0009 (Adjusted p-value using graphical approach to control the overall type 1 error rate for multiple comparisons.) · Least squares mean difference: -2.13 · 95% CI -3.13 to -1.13MMRM model=treatment group,visit,stratification by acute medication overuse,migraine prevention medication use and number of failures,region,and treatment group-by-visit as fixed factors and baseline and baseline-by-visit interaction as covariates.
SecondaryChange From Baseline in Mean Monthly Acute Medication Use Days Across 12-Week Treatment Period in Off-treatment Hypothetical Estimand Population

An acute medication use day is defined as any day on which a participant reports, per eDiary, the intake of allowed medication(s) to treat an acute migraine. The monthly (4-week) acute medication use days were defined as the total number of reported acute medication use days in the diary divided by the total number of days with diary records during each 4-week period and multiplied by 28. Each 4-week period was averaged. Baseline is defined as the number of migraine days during the last 28 days prior to the randomization date. A negative change from Baseline indicates improvement. A contrast from MMRM was used to obtain the average treatment effects across the 12-week treatment period.

Time frame:
Baseline to Week 12
Reported as:
Median · acute medication use days per month
Change From Baseline in Mean Monthly Acute Medication Use Days Across 12-Week Treatment Period in Off-treatment Hypothetical Estimand Population
acute medication use days per monthPlaceboAtogepant 30 mg BIDAtogepant 60 mg QD
Change From Baseline in Mean Monthly Acute Medication Use Days Across 12-Week Treatment Period in Off-treatment Hypothetical Estimand Population-3.56 (-23.7 to 20.7)-6.21 (-26.1 to 7.4)-6.00 (-26.0 to 14.2)
Statistical analysis
  • Placebo vs Atogepant 30 mg BID · MMRM · p = 0.0002 (Adjusted p-value using graphical approach to control the overall type 1 error rate for multiple comparisons.) · Least squares mean difference: -2.52 · 95% CI -3.52 to -1.53MMRM model=treatment group,visit,stratification by acute medication overuse,migraine prevention medication use and number of failures,region,and treatment group-by-visit as fixed factors and baseline and baseline-by-visit interaction as covariates.
  • Placebo vs Atogepant 60 mg QD · MMRM · p = 0.0024 · Least squares mean difference: -2.09 · 95% CI -3.09 to -1.10
SecondaryPercentage of Participants With at Least a 50% Reduction in 3-Month Average of Monthly Migraine Days in mITT Population

Data is reported for 50% responders averaged at each 4-week period. 50% responders are participants with at least a 50 percent reduction from baseline in 3-month average of monthly migraine days. Participants recorded daily duration of migraine in a diary. A migraine day was any calendar day on which the participant experienced a migraine headache. The monthly (4-week) migraine days is equal to total number of reported migraine days in diary divided by total number of days with diary records in each 4-week period multiplied by 28. The values are rounded off to the first decimal value.

Time frame:
Baseline to Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With at Least a 50% Reduction in 3-Month Average of Monthly Migraine Days in mITT Population
percentage of participantsPlaceboAtogepant 30 mg BIDAtogepant 60 mg QD
Percentage of Participants With at Least a 50% Reduction in 3-Month Average of Monthly Migraine Days in mITT Population26.042.741.0
Statistical analysis
  • Placebo vs Atogepant 30 mg BID · Logistic regression · p = 0.0003 (Adjusted p-value using graphical approach to control the overall type 1 error rate for multiple comparisons.) · Odds ratio (or): 2.13 · 95% CI 1.45 to 3.14Logistic regression for each atogepant group versus placebo with baseline monthly migraine days as covariate,stratification of region,acute medication overuse,migraine prevention medication and number of failures,treatment group as fixed factors.
  • Placebo vs Atogepant 60 mg QD · Logistic regression · p = 0.0009 (Adjusted p-value using graphical approach to control the overall type 1 error rate for multiple comparisons.) · Odds ratio (or): 2.04 · 95% CI 1.38 to 3.00Logistic regression for each atogepant group versus placebo with baseline monthly migraine days as covariate,stratification of region,acute medication overuse,migraine prevention medication and number of failures,treatment group as fixed factors.
SecondaryPercentage of Participants With at Least a 50% Reduction in 3-Month Average of Monthly Migraine Days in Off-Treatment Hypothetical Estimand Population

Data is reported for 50% responders averaged at each 4-week period. 50% responders are participants with at least a 50 percent reduction from baseline in 3-month average of monthly migraine days. Participants recorded daily duration of migraine in a diary. A migraine day was any calendar day on which the participant experienced a migraine headache. The monthly (4-week) migraine days is equal to total number of reported migraine days in diary divided by total number of days with diary records in each 4-week period multiplied by 28. The values are rounded off to the first decimal value.

Time frame:
Baseline to Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With at Least a 50% Reduction in 3-Month Average of Monthly Migraine Days in Off-Treatment Hypothetical Estimand Population
percentage of participantsPlaceboAtogepant 30 mg BIDAtogepant 60 mg QD
Percentage of Participants With at Least a 50% Reduction in 3-Month Average of Monthly Migraine Days in Off-Treatment Hypothetical Estimand Population26.542.140.1
Statistical analysis
  • Placebo vs Atogepant 30 mg BID · Logistic regression · p = 0.0006 (Adjusted p-value using graphical approach to control the overall type 1 error rate for multiple comparisons.) · Odds ratio (or): 2.03 · 95% CI 1.38 to 2.98Logistic regression for each atogepant group versus placebo with baseline monthly migraine days as covariate,stratification of region,acute medication overuse,migraine prevention medication and number of failures,treatment group as fixed factors.
  • Placebo vs Atogepant 60 mg QD · Logistic regression · p = 0.0009 (Adjusted p-value using graphical approach to control the overall type 1 error rate for multiple comparisons.) · Odds ratio (or): 1.90 · 95% CI 1.29 to 2.79Logistic regression for each atogepant group versus placebo with baseline monthly migraine days as covariate,stratification of region,acute medication overuse,migraine prevention medication and number of failures,treatment group as fixed factors.
SecondaryChange From Baseline in Migraine Specific Quality of Life Questionnaire, Version 2.1 (MSQ v2.1) Role Function-Restrictive Domain Score at Week 12 in Off-Treatment Hypothetical Estimand Population

The MSQ v2.1 is a 14-item questionnaire designed to measure health-related quality of life impairments attributed to migraine in the past 4 weeks. It is divided into 3 domains: Role Function Restrictive (question numbers 1-7, score ranges 7 to 42) assesses how migraines limit one's daily social and work-related activities; Role Function Preventive (question numbers 8-11, score ranges 4 to 24) assesses how migraines prevent these activities; and the Emotional Function (question numbers 12-14, score ranges 3 to 18) domain assesses the emotions associated with migraines. Participants respond to items using a 6-point scale ranging from none of the time to all of the time. Raw dimension scores are computed as a sum of item responses and rescaled to a 0 to 100 scale, where higher scores indicate better quality of life. A contrast from MMRM was used to obtain the average treatment effects across the 12-week treatment period.

Time frame:
At Week 12
Reported as:
Mean · score on a scale
Change From Baseline in Migraine Specific Quality of Life Questionnaire, Version 2.1 (MSQ v2.1) Role Function-Restrictive Domain Score at Week 12 in Off-Treatment Hypothetical Estimand Population
score on a scalePlaceboAtogepant 30 mg BIDAtogepant 60 mg QD
Change From Baseline in Migraine Specific Quality of Life Questionnaire, Version 2.1 (MSQ v2.1) Role Function-Restrictive Domain Score at Week 12 in Off-Treatment Hypothetical Estimand Population17.56 ± 21.90125.73 ± 23.13723.72 ± 24.335
Statistical analysis
  • Placebo vs Atogepant 30 mg BID · MMRM · p = 0.0006 (Adjusted p-value using graphical approach to control the overall type 1 error rate for multiple comparisons.) · Least squares mean difference: 7.43 · 95% CI 3.77 to 11.09MMRM model=treatment group,visit,stratification by acute medication overuse,migraine prevention medication use and number of failures,region,and treatment group-by-visit as fixed factors and baseline and baseline-by-visit interaction as covariates.
  • Placebo vs Atogepant 60 mg QD · MMRM · p = 0.0024 (Adjusted p-value using graphical approach to control the overall type 1 error rate for multiple comparisons.) · Least squares mean difference: 5.78 · 95% CI 2.15 to 9.41MMRM model=treatment group,visit,stratification by acute medication overuse,migraine prevention medication use and number of failures,region,and treatment group-by-visit as fixed factors and baseline and baseline-by-visit interaction as covariates.
SecondaryChange From Baseline in Mean Monthly Performance of Daily Activities Domain Score of the AIM-D Across 12-Week Treatment Period in mITT Population

The AIM-D is a 11-item patient-reported outcome (PRO) measure that assesses the impact of migraine on the performance of daily activities which include, 7 items: difficulty with household chores, errands, leisure activities at home, leisure or social activities outside the home, strenuous physical activities, concentrating, and thinking clearly and physical impairment; 4 items: difficulty walking, moving body, bending forward, moving head using a 6-point rating scale where 0=not difficult at all, 1=a little difficult, 2=somewhat difficult, 3=very difficult, 4=extremely difficult, and 5=I could not do it at all. The raw performance of daily activities domain scores were transformed to 0-100 scale, with higher scores indicating greater impact of migraine (higher disease burden). A contrast from MMRM was used to obtain the average treatment effects across the 12-week treatment period.

Time frame:
Baseline to Week 12
Reported as:
Mean · score on a scale
Change From Baseline in Mean Monthly Performance of Daily Activities Domain Score of the AIM-D Across 12-Week Treatment Period in mITT Population
score on a scalePlaceboAtogepant 30 mg BIDAtogepant 60 mg QD
Change From Baseline in Mean Monthly Performance of Daily Activities Domain Score of the AIM-D Across 12-Week Treatment Period in mITT Population-9.80 ± 11.311-14.56 ± 13.042-13.90 ± 12.625
Statistical analysis
  • Placebo vs Atogepant 30 mg BID · MMRM · p = 0.0003 (Adjusted p-value using graphical approach to control the overall type 1 error rate for multiple comparisons.) · Least squares mean difference: -4.85 · 95% CI -6.75 to -2.95MMRM model=treatment group,visit,stratification by acute medication overuse,migraine prevention medication use and number of failures,region,and treatment group-by-visit as fixed factors and baseline and baseline-by-visit interaction as covariates.
  • Placebo vs Atogepant 60 mg QD · MMRM · p = 0.0009 (Adjusted p-value using graphical approach to control the overall type 1 error rate for multiple comparisons.) · Least squares mean difference: -3.38 · 95% CI -5.27 to -1.49MMRM model=treatment group,visit,stratification by acute medication overuse,migraine prevention medication use and number of failures,region,and treatment group-by-visit as fixed factors and baseline and baseline-by-visit interaction as covariates.
SecondaryChange From Baseline in Mean Monthly Physical Impairment Domain Score of the AIM-D Across 12-Week Treatment Period in mITT Population

The AIM-D is a 11-item PRO measure that assesses the impact of migraine on the performance of daily activities which includes 7 items: difficulty with household chores, errands, leisure activities at home, leisure or social activities outside the home, strenuous physical activities, concentrating, and thinking clearly and physical impairment; 4 items: difficulty walking, moving body, bending forward, moving head using a 6-point rating scale where 0=not difficult at all, 1=a little difficult, 2=somewhat difficult, 3=very difficult, 4=extremely difficult, and 5=I could not do it at all. The raw physical impairment domain scores were transformed to 0-100 scale, with higher scores indicating greater impact of migraine (higher disease burden). A contrast from MMRM was used to obtain the average treatment effects across the 12-week treatment period.

Time frame:
Baseline to Week 12
Reported as:
Mean · score on a scale
Change From Baseline in Mean Monthly Physical Impairment Domain Score of the AIM-D Across 12-Week Treatment Period in mITT Population
score on a scalePlaceboAtogepant 30 mg BIDAtogepant 60 mg QD
Change From Baseline in Mean Monthly Physical Impairment Domain Score of the AIM-D Across 12-Week Treatment Period in mITT Population-8.05 ± 10.923-12.34 ± 12.237-11.65 ± 12.172
Statistical analysis
  • Placebo vs Atogepant 30 mg BID · MMRM · p = 0.0003 (Adjusted p-value using graphical approach to control the overall type 1 error rate for multiple comparisons.) · Least squares mean difference: -4.19 · 95% CI -5.95 to -2.43MMRM model=treatment group,visit,stratification by acute medication overuse,migraine prevention medication use and number of failures,region,and treatment group-by-visit as fixed factors and baseline and baseline-by-visit interaction as covariates.
  • Placebo vs Atogepant 60 mg QD · MMRM · p = 0.0025 (Adjusted p-value using graphical approach to control the overall type 1 error rate for multiple comparisons.) · Least squares mean difference: -2.71 · 95% CI -4.47 to -0.96MMRM model=treatment group,visit,stratification by acute medication overuse,migraine prevention medication use and number of failures,region,and treatment group-by-visit as fixed factors and baseline and baseline-by-visit interaction as covariates.
SecondaryChange From Baseline in the Headache Impact Test (HIT-6) Total Score at Week 12 in Off-Treatment Hypothetical Estimand Population

HIT-6 is a 6-question assessment used to measure the impact headaches have on a participant's ability to function on the job, at school, at home, and in social situations. It assesses the effect that headaches have on normal daily life and the participant's ability to function. Responses are based on frequency using a 5-point scale ranging from "never" to "always." The HIT-6 total score, which ranges from 36 to 78, is the sum of the responses - each of which is assigned a score ranging from 6 points (never) to 13 points (always). MMRM was used for the analyses.

Time frame:
At Week 12
Reported as:
Mean · score on a scale
Change From Baseline in the Headache Impact Test (HIT-6) Total Score at Week 12 in Off-Treatment Hypothetical Estimand Population
score on a scalePlaceboAtogepant 30 mg BIDAtogepant 60 mg QD
Change From Baseline in the Headache Impact Test (HIT-6) Total Score at Week 12 in Off-Treatment Hypothetical Estimand Population-5.18 ± 6.682-8.97 ± 8.475-7.97 ± 8.209
Statistical analysis
  • Placebo vs Atogepant 30 mg BID · MMRM · p = 0.0006 · Least squares mean difference: -3.30 · 95% CI -4.67 to -1.93MMRM model=treatment group,visit,stratification by acute medication overuse,migraine prevention medication use and number of failures,region,and treatment group-by-visit as fixed factors and baseline and baseline-by-visit interaction as covariates.
  • Placebo vs Atogepant 60 mg QD · MMRM · p = 0.0024 · Least squares mean difference: -2.66 · 95% CI -4.02 to -1.30MMRM model=treatment group,visit,stratification by acute medication overuse,migraine prevention medication use and number of failures,region,and treatment group-by-visit as fixed factors and baseline and baseline-by-visit interaction as covariates.

Adverse events

Collected over From first dose of study drug up to end of study (Up to approximately 16 weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/259 (0%)3/255 (1.2%)16/255 (6.3%)
Atogepant 30 mg BID0/257 (0%)4/257 (1.6%)44/257 (17.1%)
Atogepant 60 mg QD0/262 (0%)7/261 (2.7%)46/261 (17.6%)
Most frequent serious events
Showing 10 of 15
Most frequent serious events
EventPlaceboAtogepant 30 mg BIDAtogepant 60 mg QD
EPICONDYLITISInjury, poisoning and procedural complications1/2550/2570/261
PLASMA CELL MYELOMANeoplasms benign, malignant and unspecified (incl cysts and polyps)1/2550/2570/261
SUICIDE ATTEMPTPsychiatric disorders1/2551/2570/261
ANAL ABSCESSInfections and infestations0/2551/2570/261
COVID-19 PNEUMONIAInfections and infestations0/2551/2570/261
BENIGN OVARIAN TUMOURNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/2551/2570/261
CHOLELITHIASISHepatobiliary disorders0/2550/2571/261
COVID-19Infections and infestations0/2550/2571/261
FALLInjury, poisoning and procedural complications0/2550/2571/261
HIP FRACTUREInjury, poisoning and procedural complications0/2550/2571/261
Most frequent other events
Most frequent other events
EventPlaceboAtogepant 30 mg BIDAtogepant 60 mg QD
CONSTIPATIONGastrointestinal disorders8/25528/25726/261
NAUSEAGastrointestinal disorders9/25520/25725/261

Baseline characteristics

Intent-to-treat (ITT) population included all randomized participants.

Age, Continuous
Age, Continuous(years)PlaceboAtogepant 30 mg BIDAtogepant 60 mg QDTotal
Mean42.0 ± 12.4342.6 ± 11.8941.7 ± 12.3042.1 ± 12.20
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboAtogepant 30 mg BIDAtogepant 60 mg QDTotal
Female229227226682
Male30303696
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboAtogepant 30 mg BIDAtogepant 60 mg QDTotal
Hispanic or Latino1312631
Not Hispanic or Latino246245256747
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboAtogepant 30 mg BIDAtogepant 60 mg QDTotal
American Indian or Alaska Native1113
Asian959593283
Native Hawaiian or Other Pacific Islander1001
Black or African American78924
White154151157462
More than one race1225
Unknown or Not Reported0000
Monthly Migraine Days in mITT Population
Monthly Migraine Days in mITT Population(migraine days per month)PlaceboAtogepant 30 mg BIDAtogepant 60 mg QDTotal
Median18.00 (8.0 to 28.0)18.00 (8.0 to 28.0)19.00 (9.0 to 28.0)18.2 (8.0 to 28.0)
Monthly Migraine Days in Off-Treatment Hypothetical Estimand Population
Monthly Migraine Days in Off-Treatment Hypothetical Estimand Population(migraine days per month)PlaceboAtogepant 30 mg BIDAtogepant 60 mg QDTotal
Median18.0 (8 to 28)18.0 (8 to 28)19.0 (9 to 28)18.3 (8 to 28)
08

Study locations

150 sites
  • Barrow Neuro Institute /ID# 236776
    Phoenix, Arizona 85013, United States
  • Baptist Health Center for Clinical Research /ID# 237361
    Little Rock, Arkansas 72205, United States
  • California Headache and Balance Center /ID# 236246
    Fresno, California 93720, United States
  • Wr-Pri Llc /Id# 236008
    Los Alamitos, California 90720, United States
  • Pharmacology Research Institute (PRI) - Newport Beach (Wake) /ID# 237692
    Newport Beach, California 92660, United States
  • Schuster Medical Research Institute /ID# 236447
    Sherman Oaks, California 91403, United States
  • Alpine Clinical Research Center /ID# 234346
    Boulder, Colorado 80301-1880, United States
  • George Washington University Medical Faculty Associates /ID# 238011
    Washington, District of Columbia 20037-3201, United States
  • Accel Research Sites - St Petersburg Clinical Research Unit /ID# 237161
    Saint Petersburg, Florida 33709-3113, United States
  • Accel Research Sites - Tampa Clinical Research Unit /ID# 237485
    Tampa, Florida 33634, United States
  • Premiere Research Institute - Palm Beach /ID# 238192
    West Palm Beach, Florida 33407-3209, United States
  • NeuroTrials Research Inc. /ID# 237364
    Atlanta, Georgia 30328, United States
  • Josephson-Wallack-Munshower Neurology - NE /ID# 238234
    Indianapolis, Indiana 46256-4692, United States
  • Collective Medical Research /ID# 236400
    Prairie Village, Kansas 66208, United States
  • Ochsner Clinic Foundation /ID# 236543
    Covington, Louisiana 70433-8107, United States
  • Beth Israel Deaconess Medical Center /ID# 237540
    Boston, Massachusetts 02215-5400, United States
  • BTC of New Bedford /ID# 236384
    New Bedford, Massachusetts 02740, United States
  • Clinical Research Institute, Inc /ID# 238299
    Minneapolis, Minnesota 55402-2606, United States
  • Headache Neurology Research Institute /ID# 236464
    Ridgeland, Mississippi 39157, United States
  • Nevada Headache Institute /ID# 236420
    Las Vegas, Nevada 89113, United States
  • Dartmouth-Hitchcock Medical Center /ID# 237444
    Lebanon, New Hampshire 03756, United States
  • Albuquerque Clinical Trials, Inc /ID# 236853
    Albuquerque, New Mexico 87102, United States
  • Albany Medical Center Rheumatology /ID# 236540
    Albany, New York 12208-3412, United States
  • Dent Neurosciences Research Center, Inc. /ID# 237040
    Amherst, New York 14226, United States
  • Headache Wellness Center /ID# 236431
    Greensboro, North Carolina 27405, United States
  • Raleigh Neurology Associates /ID# 237141
    Raleigh, North Carolina 27607, United States
  • Stetson-University of Cincinnati /ID# 236453
    Cincinnati, Ohio 45219, United States
  • Abington Neurological Associates - Abington /ID# 236258
    Abington, Pennsylvania 19001, United States
  • Preferred Primary Care Physicians, Inc. /ID# 236439
    Pittsburgh, Pennsylvania 15236, United States
  • WR-ClinSearch /ID# 238288
    Chattanooga, Tennessee 37421-1605, United States
  • Clinical Neuroscience Solutions - Memphis /ID# 237478
    Memphis, Tennessee 38119, United States
  • DiscoveResearch, Inc /ID# 236274
    Bryan, Texas 77802, United States
  • Texas Neurology /ID# 236359
    Dallas, Texas 75214, United States
  • University of Texas Southwestern Medical Center /ID# 236941
    Dallas, Texas 75390-7208, United States
  • J. Lewis Research, Inc. / Foothill Family Clinic /ID# 236395
    Salt Lake City, Utah 84109, United States
  • J. Lewis Research, Inc. Foothill Family Clinic South /ID# 236297
    Salt Lake City, Utah 84121, United States
  • Highland Clinical Research /ID# 237816
    Salt Lake City, Utah 84124, United States
  • MedStar Georgetown Neurology /ID# 236324
    McLean, Virginia 22101, United States
  • Sentara Neurology Specialists - Virginia Beach /ID# 234349
    Virginia Beach, Virginia 23456-0019, United States
  • Northwest Clinical Research Center /ID# 237581
    Bellevue, Washington 98007, United States
  • Puget Sound Neurology /ID# 236321
    Tacoma, Washington 25328, United States
  • Royal North Shore Hospital /ID# 237008
    St Leonards, New South Wales 2065, Australia
  • The Royal Melbourne Hospital /ID# 236859
    Parkville, Victoria 3050, Australia
  • CHAMP Clinic /ID# 236252
    Calgary, Alberta T3M 1M4, Canada
  • Vancouver Island Health Authority /ID# 238053
    Victoria, British Columbia V8R 1J8, Canada
  • Ottawa Headache Centre Research Inc /ID# 236432
    Ottawa, Ontario K2G 6E2, Canada
  • Clinique des cephalees de Montreal /ID# 236266
    Montreal, Quebec H2W 1V1, Canada
  • Montreal Neurological Institut /ID# 236329
    Montreal, Quebec H3A 2B4, Canada
  • Peking University Third Hospital /ID# 238150
    Beijing, Beijing 100191, China
  • Chinese PLA General Hospital /ID# 238237
    Beijing, Beijing 100853, China
  • Guangzhou First People's Hospital /ID# 236510
    Guangzhou, Guangdong 510180, China
  • The Second Affiliated Hospital of Guangzhou Medical University /ID# 238133
    Guangzhou, Guangdong 510260, China
  • Hubei General Hospital /ID# 236486
    Wuhan, Hebei 430060, China
  • The First Affiliated Hospital of Zhengzhou University /ID# 237025
    Zhengzhou, Henan 450052, China
  • Jiangsu Province Hospital /ID# 237846
    Nanjing, Jiangsu 210029, China
  • The Second Hospital of Jilin University /ID# 236520
    Changchun, Jilin 130022, China
  • Ruijin Hospital, Shanghai Jiaotong University School of Medicine /ID# 237847
    Shanghai, Shanghai 200065, China
  • The Second Hospital of Shanxi Medical University /ID# 236529
    Taiyuan, Shanxi 030000, China
  • The second Affiliated hospital of Zhejiang University school of Medicine /ID# 238260
    Hangzhou, Zhejiang 310009, China
  • Sir Run Run Shaw Hospital Zhejiang University School of Medicine /ID# 236500
    Hangzhou, Zhejiang 310020, China
  • Beijing Friendship Hospital /ID# 237264
    Beijing, 100032, China
  • The Second Hospital of Soochow University /ID# 234296
    Suzhou, 215004, China
  • Tianjin Huanhu Hospital (THH) /ID# 236524
    Tianjin, 300350, China
  • Tongji Hospital Tongji Medical College of HUST /ID# 237835
    Wuhan, 430030, China
  • NEUROHK s.r.o. /ID# 236290
    Hradec Kralove, 500 09, Czechia
  • BRAIN-SOULTHERAPY s.r.o. /ID# 236380
    Kladno, 272 01, Czechia
  • CCR Ostrava, s.r.o. /ID# 234291
    Ostrava, 702 00, Czechia
  • CLINTRIAL s.r.o. /ID# 237793
    Prague 10, 100 00, Czechia
  • CCR Czech a.s /ID# 236249
    Prague 4, 140 00, Czechia
  • FORBELI s.r.o. /ID# 236427
    Prague, 160 00, Czechia
  • CCR Prague s.r.o. /ID# 236250
    Praha, 130 00, Czechia
  • Thomayerova nemocnice /ID# 237175
    Praha, 140 59, Czechia
  • NeuroMed Zlin s.r.o. /ID# 236416
    Zlin, 760 01, Czechia
  • Rigshospitalet Glostrup /ID# 236411
    Glostrup, Hovedstaden 2600, Denmark
  • AP-HM - Hopital de la Timone /ID# 236285
    Marseille CEDEX 05, Bouches-du-Rhone 13385, France
  • CH Annecy Genevois Site Annecy /ID# 236385
    PRINGY cedex, Haute-Savoie 74374, France
  • Hôpital Pierre Wertheimer /ID# 236969
    Bron, 69677, France
  • CHU Gabriel Montpied /ID# 237323
    Clermont Ferrand, 63000, France
  • Charite Universitaetsklinikum Berlin - Campus Virchow /ID# 237256
    Berlin, 13353, Germany
  • Praxis Dr. Gendolla /ID# 236311
    Essen, 45133, Germany
  • Universitaetsklinikum Essen /ID# 237209
    Essen, 45147, Germany
  • CTC North GmbH & Co. KG /ID# 236328
    Hamburg, 20251, Germany
  • Vitos Orthopaedische Klinik Kassel gemeinnuetzige GmbH /ID# 236723
    Kassel, 34131, Germany
  • Schmerzklinik Kiel /ID# 236444
    Kiel, 24149, Germany
  • LMU Klinikum Campus Grosshadern /ID# 236293
    München, 81377, Germany
  • Azienda Ospedaliera Universitaria Consorziale Policlinico /ID# 237492
    Bari, 70124, Italy
  • Azienda Ospedaliero Universitaria Careggi /ID# 237598
    Florence, 50134, Italy
  • Fondazione IRCCS Istituto Neurologico Carlo Besta /ID# 237291
    Milan, 20133, Italy
  • AOU Universita degli Studi della Campania Luigi Vanvitelli /ID# 236361
    Napoli, 80138, Italy
  • Universita di Pavia /ID# 236363
    Pavia, 27100, Italy
  • IRCCS San Raffaele Pisana /ID# 236552
    Rome, 00163, Italy
  • Takanoko Hospital /ID# 234564
    Matsuyama-shi, Ehime 790-0925, Japan
  • Fukuiken Saiseikai Hospital /ID# 236794
    Fukui-shi, Fukui 918-8235, Japan
  • Higashi Sapporo Neurology and Neurosurgery Clinic /ID# 234549
    Sapporo-shi, Hokkaido 003-0003, Japan
  • Konan Medical Center /ID# 236230
    Kobe-shi, Hyogo 658-0064, Japan
  • Atsuchi Neurosurgical Hospital /ID# 234779
    Kagoshima-shi, Kagoshima 892-0842, Japan
  • Tokai University Hospital /ID# 237595
    Isehara-shi, Kanagawa 259-1193, Japan
  • Fujitsu Clinic /ID# 237443
    Kawasaki-shi, Kanagawa 211-8588, Japan
  • Umenotsuji Clinic /ID# 234495
    Kochi-shi, Kochi 780-8011, Japan
  • Sendai Headache and Neurology Clinic Medical Corporation /ID# 234496
    Sendai-shi, Miyagi 982-0014, Japan

Showing the first 100 of 150 sites across 17 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Boinpally R, McNamee B, Yao L, Butler M, McGeeney D, Borbridge L, Periclou A. A Single Supratherapeutic Dose of Atogepant Does Not Affect Cardiac Repolarization in Healthy Adults: Results From a Randomized, Single-Dose, Phase 1 Crossover Trial. Clin Pharmacol Drug Dev. 2021 Sep;10(9):1099-1107. doi: 10.1002/cpdd.940. Epub 2021 May 4. PubMed 33942560 ↗
  • Min KC, Kraft WK, Bondiskey P, Colon-Gonzalez F, Liu W, Xu J, Panebianco D, Mixson L, Dockendorf MF, Matthews CZ, Boinpally R. Atogepant Is Not Associated With Clinically Meaningful Alanine Aminotransferase Elevations in Healthy Adults. Clin Transl Sci. 2021 Mar;14(2):599-605. doi: 10.1111/cts.12917. Epub 2020 Nov 24. PubMed 33142014 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols, analyses plans, clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: For details on when studies are available for sharing visit, please refer to the link below.

Access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Use Agreement (DUA). For more information on the process, or to submit a request, visit the following link.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2019 to primary completion in Jan 2022, 34 months.

Results were first posted in Feb 2023, 1 year after primary completion.

Of 114 industry-sponsored phase 3 interventional studies under Migraine Disorders, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 31. This study's 34 months is above that.

Counting every sponsor, half of 140 studies reached it within 19 months; a quarter within 12 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 25, 2019
First posted
Feb 26, 2019
StartActual
Mar 11, 2019
Primary completionActual
Jan 20, 2022
CompletionActual
Jan 20, 2022
Results first posted
Feb 14, 2023
Last update
Feb 14, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 14, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03855137
Lead sponsor
Allergan
Responsible party
Sponsor
First posted
Feb 26, 2019
Start date
Mar 11, 2019
Primary completion
Jan 20, 2022
Completion
Jan 20, 2022
Results posted
Feb 14, 2023
Last update
Feb 14, 2023

Study contacts

ALLERGAN INC.
study director · Allergan

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Atogepant

Start the discussion